Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2020 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates

SAN DIEGO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, announced that it has been notified by The Nasdaq Stock Market LLC that the...
February 05, 2020 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference

SAN DIEGO, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
January 30, 2020 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

SAN DIEGO, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, announced that it was notified by the Nasdaq Office of General Counsel that...
January 15, 2020 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update

SAN DIEGO, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
December 18, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study

SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared...
December 11, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

SAN DIEGO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based...
December 10, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems

SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it will give one of the feature presentations at the...
November 21, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

SAN DIEGO, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARÉ), a leader in women’s health innovation, today announced the closing of the previously announced acquisition by merger...
November 14, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update

SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2019...
November 12, 2019 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate

Across all women and all cycles evaluated, Ovaprene prevented essentially all sperm from entering the cervical canal, a surrogate marker for contraceptive effectiveness.Currently marketed...

Next Page keyboard_arrow_right